Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401.
Bergh J, Wiklund T, Erikstein B, Fornander T, Bengtsson NO, Malmström P, Kellokumpu-Lehtinen P, Anker G, Bennmarker H, Wilking N. Bergh J, et al. Among authors: bengtsson no. Ann Oncol. 1998 Apr;9(4):403-11. doi: 10.1023/a:1008252014312. Ann Oncol. 1998. PMID: 9636831 Free article. Clinical Trial.
Multimodality treatment of 128 patients with locally advanced breast carcinoma in the era of mammography screening using standard polychemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide: prognostic and therapeutic implications.
Karlsson YA, Malmström PO, Hatschek T, Fornander TG, Söderberg M, Bengtsson NO, Jansson TE, Sjöberg SM, Bergh JC. Karlsson YA, et al. Among authors: bengtsson no. Cancer. 1998 Sep 1;83(5):936-47. Cancer. 1998. PMID: 9731898
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmström P, Kellokumpu-Lehtinen P, Bengtsson NO, Söderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N. Bergh J, et al. Among authors: bengtsson no. Lancet. 2000 Oct 21;356(9239):1384-91. doi: 10.1016/s0140-6736(00)02841-5. Lancet. 2000. PMID: 11052580 Clinical Trial.
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients.
Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P, Ostenstad B, Wist E, Valvere V, Saksela E, Paavonen T, Blomqvist C. Tynninen O, et al. Among authors: bengtsson no. Br J Cancer. 2002 Jun 17;86(12):1905-8. doi: 10.1038/sj.bjc.6600325. Br J Cancer. 2002. PMID: 12085184 Free PMC article. Clinical Trial.
Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), et al. J Natl Cancer Inst Monogr. 2010;2010(41):162-77. doi: 10.1093/jncimonographs/lgq039. J Natl Cancer Inst Monogr. 2010. PMID: 20956824 Free PMC article. Review.
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
Margolin S, Bengtsson NO, Carlsson L, Edlund P, Hellstrøm M, Karlsson P, Lidbrink E, Linderholm B, Lindman H, Malmström P, Pettersson Skøld D, Søderberg M, Villman K, Bergh J; Scandinavian Breast Group Study SBG 2004-1. Margolin S, et al. Among authors: bengtsson no. Acta Oncol. 2011 Jan;50(1):35-41. doi: 10.3109/0284186X.2010.535847. Acta Oncol. 2011. PMID: 21174610 Clinical Trial.
Dose-tailoring of FEC adjuvant chemotherapy based on leukopenia is feasible and well tolerated. Toxicity and dose intensity in the Scandinavian Breast Group phase 3 adjuvant Trial SBG 2000-1.
Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg SB, Bengtsson NO, Jakobsen E, Møller S, Lindman H, Blomqvist C. Edlund P, et al. Among authors: bengtsson no. Acta Oncol. 2011 Apr;50(3):329-37. doi: 10.3109/0284186X.2011.554435. Epub 2011 Feb 8. Acta Oncol. 2011. PMID: 21299448 Clinical Trial.
52 results